MYCRONIC AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 381.8 SEK | +2.47% |
|
+1.27% | +32.85% |
| Apr. 25 | Mycronic AB has Received Replacement Order for A Prexision 80 Evo from an Existing Customer in Asia | CI |
| Apr. 18 | Transcript : Mycronic AB, Q1 2024 Earnings Call, Apr 18, 2024 |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Semiconductor Equipment & Testing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +32.85% | 3.4B | B- | ||
| +18.14% | 121B | B | ||
| +35.54% | 101B | B+ | ||
| +10.67% | 19.99B | C+ | ||
| +5.56% | 18.87B | B+ | ||
| +35.96% | 9.77B | B+ | ||
| +24.11% | 9.34B | B | ||
| -7.97% | 7.54B | C+ | ||
| -23.57% | 6.08B | D+ | ||
| +36.78% | 5.4B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MYCR Stock
- Ratings Mycronic AB
